{"id":850174,"date":"2022-03-15T20:00:01","date_gmt":"2022-03-15T20:00:01","guid":{"rendered":"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/"},"modified":"2022-03-15T20:00:01","modified_gmt":"2022-03-15T20:00:01","slug":"japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen","status":"publish","type":"post","link":"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/","title":{"rendered":"Japan – Eisai: Economic Arrangements of Amendment to Alzheimer’s Disease Treatment Collaboration Agreement with Biogen"},"content":{"rendered":"<p> Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer’s disease collaboration agreement with Biogen Inc. separately announced today. Effective as of January 1, 2023, Eisai will receive a tiered royalty on net sales of ADUHELM rather than sharing global profits and losses. The details of the royalty rates are shown in the table below.<\/p>\n<table readabilityDataTable=\"0\">\n<tr>\n<td><img decoding=\"async\" src=\"http:\/\/www.jcnnewswire.com\/topimg\/Low_EisaiRoyaltyRate.jpg\"\/><\/td>\n<\/tr>\n<tr>\n<td><small><\/small><\/td>\n<\/tr>\n<\/table>\n<p>Economic arrangements for 2022 will remain materially unchanged with Eisai’s share of ADUHELM expenses capped at $335 million for the costs related to development, commercialization and manufacturing for the period from January 1, 2022, to December 31, 2022. <\/p>\n<p> In regards to Eisai’s financials, no revision will be made at this time to the consolidated earnings forecast for the fiscal year ending March 31, 2022. If Eisai determines that revisions are necessary based on changes including business environment, Eisai will make an announcement as soon as possible.<\/p>\n<p>*ADUHELM is a registered trademark of Biogen Inc.<\/p>\n<p> Media Inquiries:<br \/>Public Relations Department,<br \/>Eisai Co., Ltd.<br \/>+81-(0)3-3817-5120<\/p>\n<p><\/span><\/p>\n<p><span id=\"MainContent_Copyright\"><\/p>\n<p>Copyright \u00a92022 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.<\/p>\n<p><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer’s disease collaboration agreement with Biogen Inc. separately announced today. Effective as of January 1, 2023, Eisai will receive a tiered royalty on net sales of ADUHELM rather than sharing global profits and losses. The details of the royalty rates are shown [&hellip;]<\/p>\n","protected":false},"author":409519,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"tdm_status":"","tdm_grid_status":"","footnotes":""},"categories":[2],"tags":[27822,38162],"class_list":{"0":"post-850174","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-business","7":"tag-economic","8":"tag-eisai"},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.0 (Yoast SEO v24.5) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Japan - Eisai: Economic Arrangements of Amendment to Alzheimer&#039;s Disease Treatment Collaboration Agreement with Biogen - Webnewswire<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Japan - Eisai: Economic Arrangements of Amendment to Alzheimer&#039;s Disease Treatment Collaboration Agreement with Biogen\" \/>\n<meta property=\"og:description\" content=\"Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer’s disease collaboration agreement with Biogen Inc. separately announced today. Effective as of January 1, 2023, Eisai will receive a tiered royalty on net sales of ADUHELM rather than sharing global profits and losses. The details of the royalty rates are shown [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/\" \/>\n<meta property=\"og:site_name\" content=\"Webnewswire\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-15T20:00:01+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.jcnnewswire.com\/topimg\/Low_EisaiRoyaltyRate.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Japan – Eisai: Economic Arrangements of Amendment to Alzheimer’s Disease Treatment Collaboration Agreement with Biogen\",\"datePublished\":\"2022-03-15T20:00:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/\"},\"wordCount\":186,\"publisher\":{\"@id\":\"https:\/\/www.webnewswire.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/#primaryimage\"},\"thumbnailUrl\":\"http:\/\/www.jcnnewswire.com\/topimg\/Low_EisaiRoyaltyRate.jpg\",\"keywords\":[\"Economic\",\"Eisai\"],\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/\",\"url\":\"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/\",\"name\":\"Japan - Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen - Webnewswire\",\"isPartOf\":{\"@id\":\"https:\/\/www.webnewswire.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/#primaryimage\"},\"thumbnailUrl\":\"http:\/\/www.jcnnewswire.com\/topimg\/Low_EisaiRoyaltyRate.jpg\",\"datePublished\":\"2022-03-15T20:00:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/#primaryimage\",\"url\":\"http:\/\/www.jcnnewswire.com\/topimg\/Low_EisaiRoyaltyRate.jpg\",\"contentUrl\":\"http:\/\/www.jcnnewswire.com\/topimg\/Low_EisaiRoyaltyRate.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.webnewswire.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Japan – Eisai: Economic Arrangements of Amendment to Alzheimer’s Disease Treatment Collaboration Agreement with Biogen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.webnewswire.com\/#website\",\"url\":\"https:\/\/www.webnewswire.com\/\",\"name\":\"Webnewswire\",\"description\":\"Leading newswire service\",\"publisher\":{\"@id\":\"https:\/\/www.webnewswire.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.webnewswire.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.webnewswire.com\/#organization\",\"name\":\"Webnewswire\",\"url\":\"https:\/\/www.webnewswire.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.webnewswire.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.webnewswire.com\/wp-content\/uploads\/2021\/05\/WNW-Big-Logo.png\",\"contentUrl\":\"https:\/\/www.webnewswire.com\/wp-content\/uploads\/2021\/05\/WNW-Big-Logo.png\",\"width\":1280,\"height\":1280,\"caption\":\"Webnewswire\"},\"image\":{\"@id\":\"https:\/\/www.webnewswire.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\",\"url\":\"https:\/\/www.webnewswire.com\/author\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Japan - Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen - Webnewswire","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/","og_locale":"en_US","og_type":"article","og_title":"Japan - Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen","og_description":"Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer’s disease collaboration agreement with Biogen Inc. separately announced today. Effective as of January 1, 2023, Eisai will receive a tiered royalty on net sales of ADUHELM rather than sharing global profits and losses. The details of the royalty rates are shown [&hellip;]","og_url":"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/","og_site_name":"Webnewswire","article_published_time":"2022-03-15T20:00:01+00:00","og_image":[{"url":"http:\/\/www.jcnnewswire.com\/topimg\/Low_EisaiRoyaltyRate.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Written by":"","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/#article","isPartOf":{"@id":"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/"},"author":{"name":"","@id":""},"headline":"Japan – Eisai: Economic Arrangements of Amendment to Alzheimer’s Disease Treatment Collaboration Agreement with Biogen","datePublished":"2022-03-15T20:00:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/"},"wordCount":186,"publisher":{"@id":"https:\/\/www.webnewswire.com\/#organization"},"image":{"@id":"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/#primaryimage"},"thumbnailUrl":"http:\/\/www.jcnnewswire.com\/topimg\/Low_EisaiRoyaltyRate.jpg","keywords":["Economic","Eisai"],"articleSection":["Business"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/","url":"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/","name":"Japan - Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen - Webnewswire","isPartOf":{"@id":"https:\/\/www.webnewswire.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/#primaryimage"},"image":{"@id":"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/#primaryimage"},"thumbnailUrl":"http:\/\/www.jcnnewswire.com\/topimg\/Low_EisaiRoyaltyRate.jpg","datePublished":"2022-03-15T20:00:01+00:00","breadcrumb":{"@id":"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/#primaryimage","url":"http:\/\/www.jcnnewswire.com\/topimg\/Low_EisaiRoyaltyRate.jpg","contentUrl":"http:\/\/www.jcnnewswire.com\/topimg\/Low_EisaiRoyaltyRate.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.webnewswire.com\/2022\/03\/15\/japan-eisai-economic-arrangements-of-amendment-to-alzheimers-disease-treatment-collaboration-agreement-with-biogen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.webnewswire.com\/"},{"@type":"ListItem","position":2,"name":"Japan – Eisai: Economic Arrangements of Amendment to Alzheimer’s Disease Treatment Collaboration Agreement with Biogen"}]},{"@type":"WebSite","@id":"https:\/\/www.webnewswire.com\/#website","url":"https:\/\/www.webnewswire.com\/","name":"Webnewswire","description":"Leading newswire service","publisher":{"@id":"https:\/\/www.webnewswire.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.webnewswire.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.webnewswire.com\/#organization","name":"Webnewswire","url":"https:\/\/www.webnewswire.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.webnewswire.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.webnewswire.com\/wp-content\/uploads\/2021\/05\/WNW-Big-Logo.png","contentUrl":"https:\/\/www.webnewswire.com\/wp-content\/uploads\/2021\/05\/WNW-Big-Logo.png","width":1280,"height":1280,"caption":"Webnewswire"},"image":{"@id":"https:\/\/www.webnewswire.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"","url":"https:\/\/www.webnewswire.com\/author\/"}]}},"_links":{"self":[{"href":"https:\/\/www.webnewswire.com\/wp-json\/wp\/v2\/posts\/850174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.webnewswire.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.webnewswire.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.webnewswire.com\/wp-json\/wp\/v2\/users\/409519"}],"replies":[{"embeddable":true,"href":"https:\/\/www.webnewswire.com\/wp-json\/wp\/v2\/comments?post=850174"}],"version-history":[{"count":0,"href":"https:\/\/www.webnewswire.com\/wp-json\/wp\/v2\/posts\/850174\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.webnewswire.com\/wp-json\/wp\/v2\/media?parent=850174"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.webnewswire.com\/wp-json\/wp\/v2\/categories?post=850174"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.webnewswire.com\/wp-json\/wp\/v2\/tags?post=850174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}